PCSK9

(Difference between revisions)

Revision as of 09:45, 15 June 2016

Structure of human PCSK9 catalytic domain (grey) and prodomain (green) complex with LDL receptor EGF-A domain (magenta) and Ca+2 ion (PDB entry 2w2m)

Drag the structure with the mouse to rotate

@@ Line 1: / Line 1: @@
 <StructureSection load='2w2m' size='350' side='right' caption='Structure of human PCSK9 catalytic domain (grey) and prodomain (green) complex with LDL receptor EGF-A domain (magenta) and Ca+2 ion (PDB entry [[2w2m]])' scene=''>
-'''PCSK9''' or '''Proprotein Convertase Subtilisin/Kexin type 9''' is a proteinase which is an enzyme which is part of cholesterol synthesis.  PCSK9 undergoes autocatalysis producing an active enzyme from its precursor.  PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation.  Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood.  Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood.
+'''PCSK9''' or '''Proprotein Convertase Subtilisin/Kexin type 9''' is a proteinase which is part of cholesterol synthesis.  PCSK9 undergoes autocatalysis producing an active enzyme from its precursor.  PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation.  Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood.  Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood.
 ==3D structures of PCSK9==